Anergis SA, of Epalinges, Switzerland, said it closed a series B financing of CHF14.5 million (US$14.9 million) with participation from all series A investors and new private European and U.S. investors. The financing was jointly led by existing investors Sunstone Capital, Biomedinvest and Renaissance PME, as well as new investor WJFS Inc. To date, Anergis has raised a total of CHF44 million in private equity. Funds will be used to advance the firm's birch allergy vaccine Allert closer to market. The company is preparing the phase III trial program. (See BioWorld Today, Oct. 22, 2013.)
Bellicum Pharmaceuticals Inc., of Houston, set the terms for its initial public offering, planning to raise $10 million by selling 6.3 million shares at a price range of $15 to $17. The firm intends to list on Nasdaq under the symbol BLCM. Jefferies, Citi and Piper Jaffray are the joint bookrunners on the deal, expected to price during the week of Dec. 15.
Flexion Therapeutics Inc., of Burlington, Mass., said it is offering 3.5 million shares in an underwritten public offering with a 30-day option for underwriters to buy up to an added 15 percent of shares. The company's stock (NASDAQ:FLXN) closed Tuesday at $17.83, up 93 cents. BMO Capital Markets Corp. and RBC Capital Markets LLC are acting as joint book-running managers. Needham & Co. LLC is acting as lead manager and Janney Montgomery Scott and Summer Street Research Partners are serving as co-managers.
Glionova Therapeutics AB, of Stockholm, said Industrifonden has joined a SEK42 million (US$5.7 million) series A financing co-led by Novo Seeds and the company's founding investor, Healthcap, to take its lead compound GLN-1001 for treatment of glioblastoma into clinical trials. (See BioWorld Today, Nov. 14, 2014.)
Juno Therapeutics Inc., of Seattle, set terms for its initial public offering, aiming to raise $153 million by offering 9.3 million shares at a price range of $15 to $18. The firm plans to list on Nasdaq under the symbol JUNO. Morgan Stanley, J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal, expected to price during the week of Dec. 15.
Novacyt SA, of Paris, disclosed a private equity placement financing of €3.1 million (US$3.8 million). New institutional investors in the company include Alto Invest, who co-invested in the round alongside other new and existing Novacyt investors. The funds will be used for new market launches of the firm's next-generation cytology platform Novaprep in 2015, including in China and the Far East. That builds on strong sales in existing markets such as Europe and the Middle East, in which Novacyt has a growing customer base, the company said.
Prometic Life Sciences Inc., of Laval, Quebec, closed its previously disclosed bought deal public offering of common shares in the capital of the corporation through a syndicate of underwriters led by Canaccord Genuity Corp., and which included Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Ltd. Prometic issued 13.2 million shares at $1.90 each for gross proceeds of about $25 million. Underwriters earned a cash commission of 5.5 percent of the gross proceeds. The company plans to use the proceeds for the advancement of additional clinical programs relating to its orally active antifibrotic drug, PBI-4050, and new plasma-derived orphan drugs, the expansion of the clinical uses and proprietary position on some of the plasma-derived orphan drugs, and the scaling-up of the manufacturing process of plasma-derived orphan drug candidates and of follow-on drug candidates to PBI-4050.
Vanc Pharmaceuticals Inc., of Vancouver, British Columbia, said the TSX Venture Exchange has confirmed its conditional acceptance of the private placement disclosed in November of about 7.3 million units priced at 15 cents each, for proceeds of about C$1 million (US$873,844). The deal, which the company expects will be oversubscribed, will close on or about Dec. 10.
Xoma Corp., of Berkeley, Calif., priced about 8 million shares of common stock and accompanying warrants to purchase one share of common stock for each share purchased at a price to the public of $4.94. The warrants are exercisable at an exercise price of $7.90 per share beginning on the date of issuance and will expire on the second anniversary of the date of issuance. The shares and warrants will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the SEC, and Xoma expects net proceeds of about $37.7 million, not including any future proceeds from the exercise of the warrants. The offering is expected to close on or about Dec. 12. Cowen and Co. is acting as the sole placement agent. Shares of Xoma (NASDAQ:XOMA) closed Tuesday at $4.93, down 2 cents.